The relative lack of effect of anti-CSF1 contrasts with the ability of anti-RANKL (Denosumab) to produce a 40–50% decline in TRAP5b at least in individuals with elevated TRAP5b associated with osteoporosis [138, 139]. This evidence concerns the gene CSF1 and osteoporosis.